Evaluation of Pharmacist Impact on Patients Initiating Eculizumab for Atypical Hemolytic Uremic Syndrome in the Inpatient Setting

Abstract

Get full access to this article

View all access options for this article.

References

Legendre

Licht

Muus

, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181. doi:10.1056/NEJMoa1208981.

Soliris (eculizumab) [Prescribing information]. Boston, MA: Alexion Pharmaceuticals; 2020.

Walle

Delmas

Ardissino

Wang

Kincaid

Haller

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30(1):127-134. doi:10.1007/s40620-016-0288-3.

Neto

de Moraes Soler

Vasconcelos

HVG

, et al. Eculizumab interruption in atypical hemolytic uremic syndrome due to shortage: analysis of a Brazilian cohort. J Nephrol. 2021;34:1373-1380. doi:10.1007/s40620-020-00920-z.

Oliveira

Silva

Miranda

ÍKSPB

, et al. Impact of clinical pharmacy in oncology and hematology centers: a systematic review. J Oncol Pharm Pract. 2021;27(3):679-692. doi:10.1177/1078155220976801.

Uriol Rivera

Cabello Pelegrin

Ballester Ruiz

, et al. Impact of a multidisciplinary team for the management of thrombotic microangiopathy. PLoS ONE. 2018;13(11):e0206558. doi:10.1371/journal.pone.0206558.